Everolimus and Sunitinib for Treating Unresectable or Metastatic Neuroendocrine Tumours in People with Progressive Disease (TA449)

Technology Appraisal Guidance No. 449

Source: National Institute for Health and Care Excellence

1. Guidance

1.1 Everolimus and sunitinib are recommended, within their marketing authorisations, as options for treating well- or moderately differentiated unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease.

1.2 Everolimus is recommended, within its marketing authorisation, as an option for treating well-differentiated (grade 1 or grade 2) non-functional unresectable or metastatic NETs of gastrointestinal or lung origin in adults with progressive disease.

1.3 Everolimus is recommended only when the company provides it with the discount agreed in the patient access scheme.

A copy of the full document and background is available on the Internet at www.nice.org.uk/guidance/ta449

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: nice@nice.org.uk

Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease.
Issue Date: June 2017

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more